Patent intelligence · US
US 9763995
Polymer conjugates of protegrin peptides
Polymer conjugates of protegrin peptides
Patent details — US 9763995
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 19, 2017
- Expiration
- Sep 14, 2037
- Applicant
- Nektar Therapeutics
- Claims
- 9
- CPC classes
- A61K, A61K38/10, A61K47/60, A61P
Quick answer
US 9763995 (Polymer conjugates of protegrin peptides) is held by Nektar Therapeutics. Status: granted. Granted Sep 19, 2017. Expires Sep 14, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Nektar Therapeutics
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K38/10, A61K47/60, A61P, A61P31/00, A61P31/04
More from Nektar Therapeutics
Related pharmaceutical patents in our USPTO index.
-
US 12324828
Conjugates of a factor VIII moiety having an oxime-containing linkage
granted -
US 12325708
Adenosine 2 receptor antagonists
granted -
US 12247059
Conjugates of an IL-2 moiety and a polymer
granted -
US 12233104
Combination of an IL-2RBETA-selective agonist and a long-acting IL-15 agonist
granted -
US 12214045
Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods
granted -
US 12054553
Immunotherapeutic tumor treatment method
granted -
US 12036283
Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
granted -
US 12030940
Immunotherapeutic tumor treatment method
granted
Frequently asked questions
What is US patent 9763995?
US 9763995 (Polymer conjugates of protegrin peptides) is held by Nektar Therapeutics. Status: granted. Granted Sep 19, 2017. Expires Sep 14, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9763995?
Nektar Therapeutics is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 423 pharmaceutical patents for this assignee.
When does US 9763995 expire?
Our index shows an expiration date of Sep 14, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.